What are the benefits of a GLS and why are MedTech companies considering it now?
Today’s global medical device market is creating challenging conditions for device manufacturers. Being able to respond to emerging production demands, changes in regulations and the continued growth in product variations and combinations is increasingly complex.
Progressively, medical device manufacturers are recognizing that their disparate, siloed, labeling systems are introducing unacceptable levels of inefficiencies, manual overheads, and corresponding risks to their packaging and labeling operations.
Now more than ever, MedTech companies are seeking the benefits offered by a Global Labeling System (GLS), standardizing on a single, central, enterprise-wide labeling application. Thankfully, with modern technologies and standards, a GLS is now much easier to plan, implement and manage.
In this information packed session, PRISYM ID speakers will share insight into why continuing with international medical device manufacturing without the support of a true GLS, will create continual challenges, and why now is the time to take a different approach.
Chief Executive Officer, PRISYM ID
Richard has been a leader in the healthcare and technology sector for the last 30 years and brings to PRISYM ID a track record of leveraging innovation to deliver valuable solutions for customers. In previous roles as Divisional Director Healthcare at Wilmington plc and as Chief Executive Officer at Doctors.net.uk, Richard led the organizations' strategic direction, including international growth and a program of acquisitions to better serve customer needs.
VP of Global Products, PRISYM ID
Simon Jones is VP of Global Products for PRISYM ID with responsibility for managing the end-to-end lifecycle of the company’s regulated content and label management product portfolio.
Simon has 20 years of experience in delivering product strategies and product positioning which address market opportunities effectively. He is a subject matter expert in medical device and clinical trial labeling space, researching this market, identifying industry challenges, investigating market trends, and identifying where the industry is going from a technology and regulatory perspective.